Evidence map›Paper›PMID 40966319›Full record

ArticleCancer research2025

Loss of UXS1 Selectively Depletes Pyrimidines and Induces Replication Stress in KEAP1-Mutant Lung Cancer.

Melat T Gebru, Timothy E Hoffman, Aaron Boudreau, Ngoc Vu, Fei Han, Putianqi Wang, Eddie Folk, Xiumin Wu, James Newton, Kelly D Foster-Duke and 14 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Melat T GebruCalico Life Sciences LLC, South San Francisco, California.ORCID 0000-0003-0155-7786
Timothy E HoffmanCalico Life Sciences LLC, South San Francisco, California.ORCID 0000-0001-8077-867X
Aaron BoudreauCalico Life Sciences LLC, South San Francisco, California.ORCID 0009-0005-1710-7503
Ngoc VuCalico Life Sciences LLC, South San Francisco, California.ORCID 0000-0002-5323-7146
Fei HanAbbVie Inc, North Chicago, Illinois.ORCID 0000-0001-5756-1106
Putianqi WangCalico Life Sciences LLC, South San Francisco, California.ORCID 0009-0008-3386-9630
Eddie FolkCalico Life Sciences LLC, South San Francisco, California.ORCID 0009-0003-1518-4762
Xiumin WuCalico Life Sciences LLC, South San Francisco, California.ORCID 0000-0001-5537-3021
James NewtonAbbVie Inc, North Chicago, Illinois.ORCID 0009-0008-6849-6598
Kelly D Foster-DukeAbbVie Inc, North Chicago, Illinois.ORCID 0009-0005-9721-907X
Jessica GajdaAbbVie Inc, North Chicago, Illinois.ORCID 0000-0001-7841-6557
Sammy VillaCalico Life Sciences LLC, South San Francisco, California.ORCID 0000-0002-7261-4787
Nianxin YangCalico Life Sciences LLC, South San Francisco, California.ORCID 0000-0002-6842-7874
Celeste M SandovalCalico Life Sciences LLC, South San Francisco, California.ORCID 0009-0002-4520-2880
Christian GrantAbbVie Inc, Worcester, Massachusetts.ORCID 0009-0004-9427-8958
Samatha E WildeboerAbbVie Inc, North Chicago, Illinois.ORCID 0009-0005-8779-8987
Wayne R BuckAbbVie Inc, North Chicago, Illinois.ORCID 0000-0002-0698-2178
Jonathan A HicksonAbbVie Inc, North Chicago, Illinois.ORCID 0009-0008-6619-4190
Ari J FirestoneCalico Life Sciences LLC, South San Francisco, California.ORCID 0000-0001-9902-443X
Michael KortAbbVie Inc, North Chicago, Illinois.ORCID 0000-0003-3059-9790
Bryson D BennettCalico Life Sciences LLC, South San Francisco, California.ORCID 0009-0001-4640-1796
J Brad ShotwellAbbVie Inc, North Chicago, Illinois.ORCID 0000-0002-7758-146X
Noel S WilsonAbbVie Inc, North Chicago, Illinois.ORCID 0009-0006-6812-2022
David StokoeCalico Life Sciences LLC, South San Francisco, California.ORCID 0000-0002-6333-5364

Funding

AbbVie (Allergan)Calico
6 · The paper itself

Abstract

Kelch-like ECH-associated protein 1 (KEAP1) is the third most commonly mutated gene in non-small cell lung cancer and is associated with poor prognosis. In this study, we investigated synthetic lethal interaction genes in KEAP1-mutated cancer cells and identified a dependency on UDP-xylose synthase 1 (UXS1), which converts UDP-glucuronic acid (UDP-GlcA) to UDP-xylose in the proteoglycan synthetic pathway. UDP-glucose dehydrogenase (UGDH), a transcriptional target of NRF2 that converts UDP-glucose to UDP-GlcA, was highly expressed in KEAP1-mutant tumors. Upon UXS1 knockdown, depletion of UDP-xylose occurred in both KEAP1-mutant and wild-type cells, whereas UDP-GlcA accumulated to a greater extent in the KEAP1-mutant setting. The resulting shortage of available UDP and other pyrimidines slowed S-phase progression and stalled DNA replication fork marks, causing cells to undergo prolonged cell-cycle exit or apoptosis. Dependency on UXS1 was rescued by knocking out UGDH to prevent UDP-GlcA accumulation and UDP depletion. DNA replication stress in UXS1-depleted cells sensitized them to clinical cell-cycle checkpoint inhibitors. Furthermore, CRISPR screening experiments identified genes that modulate UXS1 dependency. Whereas the liver had the highest normal tissue expression of UGDH, UXS1 knockout in the liver did not result in hepatotoxicity. Taken together, these data demonstrate that UXS1 is a selective dependency in KEAP1-mutant tumors, and loss of UXS1 creates additional therapeutically exploitable vulnerabilities in KEAP1-mutant tumors. SIGNIFICANCE: UXS1 loss in KEAP1-mutant cells causes pyrimidine nucleotide depletion, DNA replication stress induction, and ultimately cell-cycle exit that results in tumor stasis, highlighting UXS1 as a potential therapeutic target in KEAP1-mutant tumors. See related commentary by Yasseen and DeNicola, p. 4582.

Indexed as

Carcinoma, Non-Small-Cell LungDNA ReplicationKelch-Like ECH-Associated Protein 1Lung NeoplasmsPyrimidinesAnimalsApoptosisCell Line, TumorHumansMiceMutationKEAP1 protein, humanKelch-Like ECH-Associated Protein 1Pyrimidines

Identifiers

PMID40966319
PMCPMC12666321

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.